Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop.
about
Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product.Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.Informing the Historical Record of Experimental Nonhuman Primate Infections with Ebola Virus: Genomic Characterization of USAMRIID Ebola Virus/H.sapiens-tc/COD/1995/Kikwit-9510621 Challenge Stock "R4368" and Its Replacement "R4415".Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection.Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.Immunology of protection from Ebola virus infection.Animal models for ebolavirus countermeasures discovery: what defines a useful model?Validation of the Filovirus Plaque Assay for Use in Preclinical StudiesEbola virus vaccines - reality or fiction?[Ebola virus disease in West Africa and Germany : clinical presentation, management and practical experience with medevacuated patients in Germany].Will We Be Ready for the Next War?Reply to Christopher and Kortepeter.Development of a Lethal Intranasal Exposure Model of Ebola Virus in the Cynomolgus Macaque.A Single Amino Acid Change in the Marburg Virus Glycoprotein Arises during Serial Cell Culture Passages and Attenuates the Virus in a Macaque Model of Disease.A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.Safeguarding against Ebola: Vaccines and therapeutics to be stockpiled for future outbreaks.
P2860
Q33826350-268BC894-85D5-48E2-A392-66BFF72C584EQ34473079-53B69739-69A0-4A18-B9E6-FD0AAFB4B44DQ35965936-F515BBAA-C538-4AD8-9782-5449F78EB24BQ36043284-B8E6ECD3-8B33-4B90-8FBE-FCB45697E34EQ36239796-5DA2E6CC-987D-4C16-88D8-9CBF29BBDB74Q38462668-937B1DC5-89DB-44F6-82CF-5CBE8BA73FAFQ38500788-1F2B1918-3905-40EC-A67D-E1964F8671FCQ38775636-68597FD0-4643-4D31-9A0C-267C9F4CA012Q38881265-83DAC838-FF85-48EB-9545-AC19ADC59D5CQ40156458-7D71C5D4-BEFB-4514-9018-E1F4886338F2Q44099520-97FA1FC5-25FA-4DF6-8F45-714A7714B7BAQ44099528-D46065E4-70D4-4C9A-B97A-BBF6382FB4E2Q44106092-F3BFB637-378D-4FF5-AA2B-0048161E9E3DQ47159182-A9A84FD7-E673-4940-B84B-5674943A9C32Q51785212-0CC945EB-2BDD-4DA1-A792-56D233B0216CQ55026054-4D7DF454-9B04-41BB-8A25-01569CC427B7
P2860
Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Challenges, progress, and oppo ...... ical countermeasures workshop.
@en
Challenges, progress, and oppo ...... ical countermeasures workshop.
@nl
type
label
Challenges, progress, and oppo ...... ical countermeasures workshop.
@en
Challenges, progress, and oppo ...... ical countermeasures workshop.
@nl
prefLabel
Challenges, progress, and oppo ...... ical countermeasures workshop.
@en
Challenges, progress, and oppo ...... ical countermeasures workshop.
@nl
P2093
P2860
P356
P1433
P1476
Challenges, progress, and oppo ...... ical countermeasures workshop.
@en
P2093
George W Christopher
Helen Schiltz
Lucy A Ward
Mark T Albrecht
Nicole Kilgore
Rebecca Kurnat
Rona Hirschberg
P2860
P304
P356
10.3390/V6072673
P577
2014-07-09T00:00:00Z